Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep biotech 1.png

The BioIndustry Association (BIA) today unveils its groundbreaking report, "Deep Biotech: Disruptive innovation for global sustainability", marking a defining moment in the UK’s science superpower ambitions. This comprehensive report not only sheds light on Deep Biotech's transformative potential but also positions the BIA as the leading voice representing innovative start-ups, scale-ups and established companies working in Deep Biotech. 

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

"We're not simply witnessing a biotech boom benefitting healthcare in the UK, the impact of this cutting-edge science runs much deeper" emphasises Steve Bates OBE, CEO of the BIA. "We're on the cusp of a biorevolution powered by Deep Biotech, and the BIA is at the forefront, as a key player in shaping the future of Deep Biotech and championing its disruptive potential." 

The BIA's Deep Biotech report serves as an invaluable new resource for companies and policymakers, delving into: 

  • The revolutionary power of Deep Biotech: Unlocking its transformative applications improving sustainability across various sectors, from energy and materials to food and the environment. 
  • Inspiring case studies:  Highlighting cutting-edge companies pioneering Deep Biotech solutions, from sustainable biofuels to lab-grown meat, including Moa Technology, Solena Materials, Phycobloom, Quest Meat and Epoch Biodesign. 
  • Challenges and opportunities: Addressing the regulatory, economic, and public acceptance hurdles Deep Biotech faces and outlining defining priorities and directions of its development to overcome them. 

 "This report is a call to action," declares Bates. "We invite policymakers, investors, and the public to join us in harnessing the immense power of Deep Biotech. Together, we can build a more sustainable, healthier future for generations to come." 

Andrew Griffith, UK Minister of State for Science, Research and Innovation, said: 

“Protecting our environment is one of the most significant challenges that we face today. This report highlights the promising solutions that biotech offers, from converting waste into useful fuel to replacing plastics with bio-based degradable materials. 

“The UK Government is backing our life sciences entrepreneurs who are working to make these solutions a reality, and through our engineering biology vision, we are supporting world-class research and development that will lead us to a more sustainable future.” 

The BIA is committed to nurturing the Deep Biotech ecosystem. Through thought leadership, advocacy, and industry events, the BIA will deliver new programmes of work in 2024 to empower Deep Biotech companies to thrive and scale, paving the way for a bio-powered future. 

Read the 'Deep Biotech: Disruptive innovation for global sustainability' report at deepbiotech.org  

 

Notes to Editors 

 

More news and updates 

BIA joins European Biosolutions Coalition

BIA has today joined the European Biosolutions Coalition, adding UK representation to this influential group. The European Biosolutions Coalition is an initiative established by several industry organisations to elevate the prominence of biosolutions on the European agenda.

New boost for TechBio companies seeking investment

The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.

State of the Discovery Nation report reveals the extent of sector's perfect storm

New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.

BIA teams up with top UK engineering biology stakeholders to champion the UK at SynBioBeta 2024

BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.

Post-Brexit border paperwork and inspections postponed for life sciences sector

Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

BIA responds to Spring Budget 2024: highlights for UK life sciences

Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

 

More within